Clik here to view.
TEAC Introduces UR-4MD: It’s Never Been So Easy to Capture & Reliably Store...
TOKYO TEAC Corporation (hereinafter TEAC) (TOKYO:6803), the world leader in medical imaging, recording and filing solutions, today announced a new high-definition medical imaging recorder to be...
View ArticleClik here to view.
Bionic Vision Australia Successfully Completes Clinical Trial of Implant in...
MELBOURNE, Australia Bionic Vision Australia (BVA), a consortium of researchers working together to develop bionic eye devices to restore a sense of vision to people with profound vision loss, today...
View ArticleClik here to view.
R-Tech Ueno: Settlement Agreement That Resolves Patent Litigation in U.S....
TOKYO R-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (“Sucampo”) announced that it, its affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Limited (Takeda), and certain...
View ArticleClik here to view.
R-Tech Ueno: Announcement of Initiation of the Phase I Clinical Trial for the...
TOKYO R-Tech Ueno (JASDAQ: 4573): We are pleased to announce that as of today, the company has started the phase one clinical trial for the new molecular entity RTU-1096, which is a vascular...
View ArticleClik here to view.
R-Tech Ueno: Sucampo and Takeda Enter into Global Licensing Agreement for...
TOKYO R-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (“Sucampo”) and Takeda Pharmaceutical Company Limited (Takeda) announced that on October 17, 2014, they have entered into a global...
View ArticleClik here to view.
Mitsui Chemicals Launched New Lens Material “UV+420cutTM”
TOKYO Mitsui Chemicals, Inc. (TOKYO:4183) (President & CEO: Tsutomu Tannowa) announced that it commenced sales of a new breakthrough ophthalmic lens material that helps protect eyes from not...
View ArticleClik here to view.
Akebia Announces Positive Top-Line Results from its Phase 2b Study of...
CAMBRIDGE, Mass. Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia...
View ArticleClik here to view.
NovaBay Pharmaceuticals Receives 2nd Major NeutroPhase Order for 150,000...
EMERYVILLE, Calif. NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today...
View ArticleClik here to view.
三井化学推出新型镜片材料”UV+420cut(TM)”
东京 (美国商业资讯)–三井化学株式会社(Mitsui Chemicals, Inc.) (TOKYO:4183)（总裁兼首席执行官：Tsutomu Tannowa）宣布，该公司已开始销售一种新型突破性镜片材料。该材料有助于保护眼睛免受紫外(10-400nm)光线辐射，同时可阻挡400nm-420nm的波长光。...
View ArticleClik here to view.
Hoya Announces Second Quarter Financial Results
TOKYO Hoya Corporation (TOKYO: 7741) today announced financial results for the second quarter ended September 30, 2014. During the quarter, revenues totaled 121,242 million yen, increasing by 18.6%...
View ArticleClik here to view.
Akebiaが慢性腎臓病に関連した貧血を伴う非透析患者を対象にAKB-6548を検討した第2b相試験で、優れて良好な結果が得られたと発表
米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — 低酸素誘導因子（HIF）の生物学を通じて腎臓病患者に革新的治療薬を提供することに傾注するバイオ製薬企業のAkebia Therapeutics,...
View ArticleClik here to view.
pSivida Corp. Reports First Quarter FY 2015 Results
WATERTOWN, Mass. pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its...
View ArticleClik here to view.
R-Tech Ueno: Completion of a Phase I/II Clinical Study of Recombinant Human...
TOKYO R-Tech Ueno (JASDAQ:4573): This is to announce the completion of a Phase I/II clinical study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) for...
View ArticleClik here to view.
pSivida Reports ILUVIEN® Granted Marketing Authorization in Belgium
WATERTOWN, Mass. pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Belgian Federal...
View ArticleClik here to view.
R-Tech Ueno: Lawsuit Claiming Infringement of AMITIZA® Capsules Patents
TOKYO R-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (“Sucampo”) announced that it, together with R-Tech Ueno, Ltd., Sucampo AG, and Takeda Pharmaceutical Company Limited (“Takeda”) and...
View ArticleClik here to view.
Presbia Flexivue Microlens™ Receives Approval from Korean Ministry of Food...
AMSTERDAM Presbia announced today that its Presbia Flexivue Microlens™ has received regulatory approval from the Korean Ministry of Food and Drug Safety (MFDS) making this new treatment option for...
View ArticleClik here to view.
R-Tech Ueno Received Orphan Drug Designation for Unoprostone Isopropyl...
TOKYO R-Tech Ueno (JASDAQ:4573): R-Tech Ueno, Ltd. today announced that we have officially received the Orphan Drug Designation from the Ministry of Health, Labour and Welfare (MHLW) for Unoprostone...
View ArticleClik here to view.
Acucela Announces That Brian O’Callaghan Will Assume the Role of CEO; Ryo...
SEATTLE Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company focused on discovering and developing novel therapeutics to treat the progression of sight-threatening ophthalmic diseases,...
View ArticleClik here to view.
JINS and Omron Healthcare Launch Joint Project in Healthcare
LAS VEGAS In response to the growing demand for sensing technology in the healthcare market, JIN Co. Ltd. (HQ: Chiyoda-ku, Tokyo; Hitoshi Tanaka, President) and Omron Healthcare Co. Ltd. (HQ: Muko,...
View ArticleClik here to view.
JINSとオムロンヘルスケア、ヘルスケア分野での共同開発プロジェクト発足
ラスベガス （ビジネスワイヤ） — 株式会社ジェイアイエヌ（東京本社：東京都千代田区、代表取締役社長：田中仁）とオムロンヘルスケア株式会社（本社：京都府向日市、代表取締役社長：宮田喜一郎）は、拡大が予想されるヘルスケア市場のセンシング・ニーズに対応するため、2016年春の商品化を目指し「JINS MEME（ジンズ...
View Article